SAŽETAK SAŽETAK Gojaznost je složen metabolički poremećaj koji predstavlja jedan od najčešćih savremenih zdravstvenih problema širom svjeta. Gojaznost i metabolički sindrom su povezani sa hroničnom inflamacijom niskog intenziteta i dislipidemijom koji su udruženi sa pojavom niza metaboličkih poremećaja uključujući kardiovaksularne bolesti, rezistenciju na insulin, dijabetes tip 2 itd. Cilj istraživanja bio je ispitati promjene u lipidnom statusu i koncentracijama markera inflamacije u serumu kod gojaznih i ispitanika sa metaboličkim sindromom.U skladu sa postavljenim ciljevima istraživanje je sprovedeno po tipu studije presjeka.Istraživanjem je obuhvaćeno 175 ispitanika koji su u skladu sa kriterijumima International Diabetes Federation podeljeni u 3 grupe: normalno uhranjeni (N=106), ispitanici sa abdominalnom gojaznošću (N=37) i treću grupu činili su ispitanici sa metaboličkim sindromom (N=32).Rezultati ovog istraživanja ukazuju na značajne promjene u lipidnom statusu i koncentracijama markera inflamacije kod gojaznih osoba i ispitanika sa metaboličkim sindromom u poređenju sa osobama normalne tjelesne mase. Uočen je porast aterogenih lipoproteina (LDL, VLDL, triacilgliceroli), smanjenje zaštitnih komponenti poput HDL-holesterola i ApoA1, kao i povišene vrijednosti inflamatornih markera (hsCRP, fibrinogen, mokraćna kiselina), što kolektivno ukazuje na povećan kardiometabolički rizik. Posebno se ističe značaj odnosa ApoB/ApoA1 kao potencijalno snažnog prediktora rizika, koji pokazuje povezanost ne samo sa dislipidemijom, već i sa sistemskom inflamacijom.Ovi nalazi podupiru potrebu za ranom identifikacijom i praćenjem biohemijskih markera u rizičnim populacijama, kako bi se pravovremeno sprovela ciljana prevencija i terapijska intervencija. Ključne riječi: gojaznost, metabolički sindrom, inflamacija, dislipidemija
Parvanova A, Reseghetti E, Abbate M, Ruggenenti P. Mechanisms and treatment of obesity-related hypertension-Part 1: Mechanisms. Clin Kidney J. 2023;17(1).
2.
Pekmezović T, Kisić Tepavčević D, Miljuš D, Marić G. Nacionalni podaci vezani za epidemiju gojaznosti u Srbiji. Epidemija gojaznosti u Srbiji. Urednik akademik Dragan Micić Beograd Srpska akademija nauka i umetnosti. 2017;
3.
Cuschieri S, Mamo J. Getting to grips with the obesity epidemic in Europe. SAGE Open Med. 2016;4(2050312116670406).
4.
Sipetić S, Bjegović-Mikanović V, Vlajinac H, Marinković J, Janković S, Z T, et al. The burden of disease preventable by risk factor reduction in Serbia. Vojnosanit Pregl. 2013;70(5):445–51.
5.
Harford KA, Reynolds CM, McGillicuddy FC, Roche HM. Fats, inflammation and insulin resistance: insights to the role of macrophage and T-cell accumulation in adipose tissue. Proc Nutr Soc. 2011;70(4):408–17.
6.
Seyedsadjadi N, Grant R. The Potential Benefit of Monitoring Oxidative Stress and Inflammation in the Prevention of Non-Communicable Diseases (NCDs. Antioxidants (Basel. 2020;10(1).
7.
S SG, K K, R D, J G. Association between obesity, inflammation and insulin resistance: Insights into signaling pathways and therapeutic interventions. Diabetes Res Clin Pract. 2023;200(110691).
8.
Masenga SK, Kabwe LS, Chakulya M, Kirabo A. Mechanisms of Oxidative Stress in Metabolic Syndrome. Int J Mol Sci. 2023;24(9).
9.
Marseglia L, Manti S, D’Angelo G, Nicotera A, Parisi E, Rosa G, et al. Stress in Obesity: A Critical Component in Human Diseases. Int J Mol Sci. 2014;16(1):378–400.
10.
Clayton TL, Fitch A, Bays HE. Obesity and hypertension: Obesity medicine association (OMA) clinical practice statement (CPS. Obes Pillars. 2023;8(100083).
11.
Ng M, Fleming T, Robinson M, Thomson B, Graetz N, C M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9945).
12.
Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. Metabolism. 201992:98–107.
13.
Kojta I, Chacińska M, Obesity BZA. Bioactive Lipids, and Adipose Tissue Inflammation in Insulin Resistance. Nutrients. 2020;12(5):1305.
14.
S SG, K K, R D, J G. Association between obesity, inflammation and insulin resistance: Insights into signaling pathways and therapeutic interventions. Diabetes Res Clin Pract. 2023;200(110691).
15.
Choi YJ, Yoon Y, Lee KY, Hien TT, Kang KW, Kim KC, et al. Uric acid induces endothelial dysfunction by vascular insulin resistance associated with the impairment of nitric oxide synthesis. FASEB J. 2014;28:3197–204.
16.
Su X, Peng D. The exchangeable apolipoproteins in lipid metabolism and obesity. Clin Chim Acta. 2020;
17.
Jiang XC. Phospholipid transfer protein: its impact on lipoprotein homeostasis and atherosclerosis. J Lipid Res. 2018;59:764–71.
18.
Zannis F, P K, G K, D E, C J, M C, et al. HDL biogenesis, remodeling, and catabolism. Handb Exp Pharmacol. 2015;224:53–111.
19.
Vaisar T, Tang C, Babenko I, Hutchins P, Wimberger J, Suffredini AF. Heinecke JW.Inflammatory remodeling of the HDL proteome impairs cholesterol efflux capacity. J Lipid Res. 2015;56:1519–30.
20.
Vekic J, Zeljkovic A, Stefanovic A, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V. Obesity and dyslipidemia. Metabolism. 2019;92:71–81.
21.
Organization WH. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i-xii:1–253.
22.
Hammarstedt A, Gogg S, Hedjazifar S, Nerstedt A, Smith U. Impaired Adipogenesis and Dysfunctional Adipose Tissue in Human Hypertrophic Obesity.
23.
Longo M, Zatterale F, Naderi J, Parrillo L, Formisano P, Raciti GA, et al. Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metaboli Complications. Int J Mol Sci. 2019;20:pii:2358.
24.
Ferranti S, D M. The Perfect Storm:Obesity, Adipocyte Dysfunction, and Metabolic Consequences. Clin Chem. 2008;54:945–55.
25.
Lee JJ, Pedley A, Hoffmann U, Massaro JM, Levy D, Long MT. Visceral and Intrahepatic Fat Are Associated with Cardiometabolic Risk Factors Above Other Ectopic FatDepots: The Framingham Heart Study. Am J Med. 2018;131:684–92.
26.
Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93:359–404.
27.
Kisić B, Sladoje DP, Mirić D, Rašić D, Novaković T. Gojaznost i posledične promjene u organizmu. PRAXIS MEDICA. 2022;51(3,4).
28.
Gustafson B. J Adipose tissue, inflammation and atherosclerosis. Atheroscler Thromb. 2010;17:332–41.
29.
World Health Organization Noncommunicable diseases country profiles 2018. 2018.
30.
Bays HE, Toth PP, Kris-Etherton PM, Abate N, Aronne LJ, Brown WV, et al. Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association. J Clin Lipidol. 2013;7:304–83.
31.
Marott SC, Nordestgaard BG, Tybjærg-Hansen A, Benn M. Components of the Metabolic Syndrome and Risk of Type 2 Diabetes. J Clin Endocrinol Metab. 2016;101:3212–3121.
32.
Dragsbæk K, Neergaard JS, Laursen JM, Hansen HB, Christiansen C, Beck-Nielsen H, et al. Metabolic syndrome and subsequent risk of type 2 diabetes and cardiovascular disease in elderly women: Challenging the current definition. Medicine (Baltimore. 2016;95:e4806.
33.
Sperling LS, Mechanick JI, Neeland IJ, Herrick CJ, Després JP, Ndumele CE, et al. The CardioMetabolic Health Alliance: Working Toward a New Care Model for the Metabolic Syndrome. J Am Coll Cardiol. 2015;66:1050–67.
34.
D PS, B K, D M. The Monitoring of Protein Markers of Inflammation and Serum Lipid Concentration in Obese Subjects with Metabolic Syndrome. J Med Biochem. 2017;36(4):366–74.
35.
D PS. Koncentracija regulatora apetita i adipocitokina u plazmi adolescenata sa gojaznošću i/ili metaboličkim sindromom. Doktorska disertacija. 2018;
36.
Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23(5):469–80.
37.
Collaboration NCDRF. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet. 2017;390(2627–42):10 1016 0140-6736 17 32129-3.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
